{"id":465,"date":"2026-08-28T06:56:05","date_gmt":"2026-08-28T06:56:05","guid":{"rendered":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/es\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","title":{"rendered":"SS-31, elamipretida y Forzinity: por qu\u00e9 es importante la distinci\u00f3n entre f\u00e1rmaco terminado"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">SS-31 y elamipretida son nombres utilizados en torno al mismo p\u00e9ptido dirigido a mitocondrias, pero Forzinity es un f\u00e1rmaco terminado espec\u00edfico aprobado por FDA con una aplicaci\u00f3n, formulaci\u00f3n, controles de fabricaci\u00f3n y etiqueta aprobados. Un nombre de ingrediente coincidente no crea equivalencia farmac\u00e9utica.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">Lo que muestra el registro<\/h2><ul class=\"wp-block-list\"><li>La indicaci\u00f3n aprobada se limita a pacientes con s\u00edndrome de Barth que pesen al menos 30 kg.<\/li><li>La aprobaci\u00f3n acelerada no elimina el requisito de evidencia confirmatoria.<\/li><li>Un lote de cat\u00e1logo SS-31 debe describirse mediante su propio registro anal\u00edtico, no tomando prestado el estado del producto aprobado.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1536\" height=\"1024\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828.png\" alt=\"Cient\u00edfico revisando im\u00e1genes de la membrana mitocondrial y datos sobre el metabolismo energ\u00e9tico\" class=\"wp-image-458\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828.png 1536w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828-300x200.png 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828-1024x683.png 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828-768x512.png 768w\" sizes=\"auto, (max-width: 1536px) 100vw, 1536px\" \/><figcaption class=\"wp-element-caption\">Ilustraci\u00f3n editorial original utilizada para identificar el tema de la investigaci\u00f3n. No representa un lote de cat\u00e1logo, medicamento aprobado, resultado de ensayo o uso cl\u00ednico.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">La frontera entre identidad y evidencia<\/h2><p class=\"wp-block-paragraph\">La aplicaci\u00f3n FDA incluye informaci\u00f3n espec\u00edfica sobre qu\u00edmica, fabricaci\u00f3n, seguridad y etiquetado del producto. Nada de eso se transfiere autom\u00e1ticamente a un material separado que lleva el nombre de elamipretida o SS-31.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Producto terminado aprobado<\/strong><span>Forzinity (elamipretida)<\/span><\/div><div class=\"pim-evidence-row\"><strong>L\u00edmite de indicaci\u00f3n<\/strong><span>s\u00edndrome de Barth; peso corporal al menos 30 kg<\/span><\/div><div class=\"pim-evidence-row\"><strong>Registro de material de investigaci\u00f3n<\/strong><span>Secuencia, forma, ensayo, impurezas y trazabilidad de lotes.<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">Qu\u00e9 pertenece al registro de materiales<\/h2><p class=\"wp-block-paragraph\">La copia de investigaci\u00f3n debe indicar cu\u00e1l es el lote del cat\u00e1logo y c\u00f3mo se prob\u00f3. No debe decir \u201cSS-31 aprobado por FDA\u201d a menos que se trate del producto terminado aprobado en su contexto regulatorio exacto.<\/p><h2 class=\"wp-block-heading\">Regla editorial<\/h2><p class=\"wp-block-paragraph\">Utilice el nombre exacto de la intervenci\u00f3n, el modelo, la poblaci\u00f3n y el criterio de valoraci\u00f3n del registro citado. No convierta una asociaci\u00f3n, mecanismo, resultado en animales, registro de medicamento terminado aprobado o prueba anal\u00edtica en una afirmaci\u00f3n sobre un lote de cat\u00e1logo no relacionado.<\/p>","protected":false},"excerpt":{"rendered":"<p>SS-31 y elamipretida son nombres utilizados en torno al mismo p\u00e9ptido dirigido a mitocondrias, pero Forzinity es un f\u00e1rmaco terminado espec\u00edfico aprobado por FDA con una aplicaci\u00f3n, formulaci\u00f3n, controles de fabricaci\u00f3n y etiqueta aprobados. Un nombre de ingrediente coincidente no crea equivalencia farmac\u00e9utica.<\/p>","protected":false},"author":1,"featured_media":630,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"364","pim_article_type":"Evidence and material-quality guide","pim_evidence_level":"FDA label\/approval distinction and research-material quality review","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"FDA Drug Trials Snapshot: Forzinity\",\"url\":\"https:\/\/www.fda.gov\/drugs\/drug-trials-snapshots\/drug-trials-snapshots-forzinity\",\"note\":\"Trial population, endpoint results and approval basis.\"},{\"title\":\"Elamipretide phase 2\/3 Barth syndrome crossover trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33077895\/\",\"note\":\"Primary published trial; PMID 33077895.\"},{\"title\":\"FDA accelerated approval announcement for Forzinity\",\"url\":\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-treatment-barth-syndrome\",\"note\":\"Approval scope and confirmatory requirement.\"}]","footnotes":""},"categories":[20],"tags":[],"class_list":["post-465","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-quality-guides"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters - NHD<\/title>\n<meta name=\"description\" content=\"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/es\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters\" \/>\n<meta property=\"og:description\" content=\"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/es\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\"},\"wordCount\":246,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\",\"articleSection\":[\"Evidence &amp; Quality Guides\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\",\"name\":\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/es\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SS-31, elamipretida y Forzinity: por qu\u00e9 es importante la distinci\u00f3n entre f\u00e1rmaco terminado - NHD","description":"SS-31 y elamipretida son nombres utilizados en torno al mismo p\u00e9ptido dirigido a mitocondrias, pero Forzinity es un f\u00e1rmaco terminado espec\u00edfico aprobado por FDA con una aprobaci\u00f3n...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/es\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","og_locale":"es_ES","og_type":"article","og_title":"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters","og_description":"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026","og_url":"https:\/\/nhdbio.com\/es\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:05+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"},"wordCount":246,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","articleSection":["Evidence &amp; Quality Guides"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","url":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","name":"SS-31, elamipretida y Forzinity: por qu\u00e9 es importante la distinci\u00f3n entre f\u00e1rmaco terminado - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"SS-31 y elamipretida son nombres utilizados en torno al mismo p\u00e9ptido dirigido a mitocondrias, pero Forzinity es un f\u00e1rmaco terminado espec\u00edfico aprobado por FDA con una aprobaci\u00f3n...","breadcrumb":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Materias primas pept\u00eddicas y s\u00edntesis personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipo t\u00e9cnico de NHD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"El equipo t\u00e9cnico de NHD mantiene documentaci\u00f3n del cat\u00e1logo de uso de investigaci\u00f3n y res\u00famenes de evidencia. Los art\u00edculos revisados \u200b\u200benlazan con art\u00edculos revisados \u200b\u200bpor pares, registros de ensayos y registros regulatorios, conservan hallazgos nulos y limitaciones de estudios, y distinguen las intervenciones publicadas de los materiales del cat\u00e1logo. Se puede utilizar dibujo asistido por AI para la estructura; los enlaces de fuentes y los l\u00edmites de las pruebas permanecen visibles. Este trabajo no es una revisi\u00f3n por pares independiente ni un consejo m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/es\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/comments?post=465"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/465\/revisions"}],"predecessor-version":[{"id":511,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/465\/revisions\/511"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media\/630"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media?parent=465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/categories?post=465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/tags?post=465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}